Skip to main content

FDA Delays Decision Over Juul's Vaping Products

FDA Delays Decision Over Juul's Vaping Products

FDA Delays Decision Over Juul's Vaping Products

Introduction

The officials of the Food & Drug Administration (FDA) of the United States delayed the decision of Juul vaping products that would decide the fate of the product in the U.S. market.

FDA banned thousands of electronic cigarettes and related products to prevent underage smoking, but the agency did not rule on Juul, which is the most popular brand among adults and teens. The agency has been repeatedly pressurized by parents, politicians and anti-tobacco advocates to ban the Juul vaping products, but the officials stated they need sufficient time and evidence to proceed.

Companies manufacturing e-cigarettes need to provide precise data about the benefits of the products to public health how they will help to reduce or quit smoking among heavy smokers and prevent smoking addiction among the underage. The companies might be able to survive in the market if they manage to provide such data.

Attorneys for the plaintiffs and families of the affected people are outraged because of the delay in the decision. They even showed concern about the growing addiction problem among teens.

E-cigarettes were introduced in the U.S. market a decade ago to provide a less harmful alternative to smokers. But as per the industry experts, the products did not serve the purpose and fueled nicotine addiction among the teens and adults who smoke.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!